Testing urine and stool samples to detect early colorectal cancer
Studies urine and stool tests to find signs of colorectal cancer or polyps early.
Plain-language title generated from the registry record
Registry title: Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
Key facts
- Where
- Reus and Tarragona, SpainSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 to 70 who had a positive stool blood test (FOBT) in the colorectal cancer early detection program and are referred for a colonoscopy.
- Age
- 50 to 70 years
- Sex
- All sexes can join
- Biomarker or test result
- A positive FOBT (stool blood) test result from the Colorectal Cancer Early Detection Program, with referral for a colonoscopy.
Main reasons for not taking part
- Another primary cancer in the last 5 years (except carcinoma in situ of the cervix or non-melanoma skin cancer)
- Severe kidney disease stage IV (creatinine clearance < 30 ml/min)
- Severe active liver disease (hepatitis, cirrhosis)
- Refusal to sign informed consent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT06452745, who can take part
Where in Spain
- Hospital Universitari Sant Joan de ReusReus, SpainContact: Josep Gumà, PhDTaking people
- Hospital Universitari Joan XXIIITarragona, SpainContact: Joan C Quer-Boniquet, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institut Investigacio Sanitaria Pere Virgili
- Trial code
- NCT06452745
- Record updated
- 2 October 2024
- Original description
Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and/or radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent.Read full original descriptionShow less
Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and/or radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent.
The purpose of the EarlyCRC project is to determine whether metabolites (substances of low molecular weight) can be found in the urine and stool of patients with colorectal cancer or polyps that can be easily and cheaply differentiated (urine or stool analysis) between the patients affected by colorectal cancer or polyps, from healthy individuals. For the identification of these possible metabolites, the urine analysis will be performed using the usual techniques in metabolomics, which studies the existing metabolites in biological processes.
Inclusion: Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.
Exclusion: Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer; Patients with severe active liver disease (hepatitis, cirrhosis); Patients with severe kidney disease stage IV (creatinine clearance < 30 ml/min); Refusal to sign informed consent.